Oncolytic measles virus strains in the treatment of gliomas

Cory Allen Mayo Clinic, Molecular Medicine Department, 200 First Street SW, Rochester, MN 55905, USA +1 507 284 2511; +1 507 284 1803; [email protected]

Georgia Paraskevakou Mayo Clinic, Molecular Medicine Department, 200 First Street SW, Rochester, MN 55905, USA +1 507 284 2511; +1 507 284 1803; [email protected]

, MD,

Chunsheng Liu Mayo Clinic, Molecular Medicine Department, 200 First Street SW, Rochester, MN 55905, USA +1 507 284 2511; +1 507 284 1803; [email protected]

, MD,

Ianko D Iankov Mayo Clinic, Molecular Medicine Department, 200 First Street SW, Rochester, MN 55905, USA +1 507 284 2511; +1 507 284 1803; [email protected]

, MD PhD,

Pavlos Msaouel Mayo Clinic, Molecular Medicine Department, 200 First Street SW, Rochester, MN 55905, USA +1 507 284 2511; +1 507 284 1803; [email protected]

Paula Zollman Mayo Clinic, Molecular Medicine Department, 200 First Street SW, Rochester, MN 55905, USA +1 507 284 2511; +1 507 284 1803; [email protected]

Rae Myers Mayo Clinic, Molecular Medicine Department, 200 First Street SW, Rochester, MN 55905, USA +1 507 284 2511; +1 507 284 1803; [email protected]

Kah Whye Peng Mayo Clinic, Molecular Medicine Department, 200 First Street SW, Rochester, MN 55905, USA +1 507 284 2511; +1 507 284 1803; [email protected]

Stephen J Russell Mayo Clinic, Molecular Medicine Department, 200 First Street SW, Rochester, MN 55905, USA +1 507 284 2511; +1 507 284 1803; [email protected]

Evanthia Galanis Mayo Clinic, Molecular Medicine Department, 200 First Street SW, Rochester, MN 55905, USA +1 507 284 2511; +1 507 284 1803; [email protected]; Mayo Clinic, Division of Medical Oncology, 200 First Street SW, Rochester, MN 55905, USA

, MD show all

Abstract

Background: Recurrent gliomas have a dismal outcome despite use of multimodality treatment including surgery, radiation therapy and chemotherapy. Objective: In this article the authors discuss potential applications of oncolytic measles virus strains as novel antitumor agents in the treatment of gliomas. Methods: Important aspects of measles virus development as an anticancer therapeutic agent including engineering, retargeting and combination studies with other therapeutic modalities are discussed. The translational process that led to the first clinical trial of an engineered measles virus derivative in patients with recurrent glioblastoma multiforme is also described. Results/conclusions: Oncolytic measles virus strains hold promise as novel antitumor agents in the treatment of gliomas.

Keywords::

Notes

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Oncolytic measles virus strains in the treatment of gliomas

Information for

Open access

Opportunities

Help and information

Oncolytic measles virus strains in the treatment of gliomas

Abstract

Notes

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature